超実践的!　抗凝固薬の使いかた

出版社： メディカ出版
著者：
発行日： 2017-04-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784840461566
電子書籍版： 2017-04-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

NOACの特徴を解説し、リスクの評価法、ガイドラインが示す治療方針、他の抗凝固薬との使い分け、合併症を有する患者や複数の選択肢がある場面での薬剤の選択法など、知りたかった抗凝固薬のすべてを盛り込んだ今まさに求められる待望の１冊。

目次

  • 超実践的！　抗凝固薬の使いかた

    ―目次―

    【序 章】
    ［1］今，なぜ抗凝固薬が注目されているのか
    ［2］抗凝固薬と抗血小板薬はここが違う

    【第 1 章　抗凝固薬の特徴を踏まえる】
    ［1］ワルファリン
    ［2］ダビガトラン
    ［3］リバーロキサバン
    ［4］アピキサバン
    ［5］エドキサバン
    ［6］ヘパリン
    ［7］フォンダパリヌクス
    ［8］ｔ−ＰＡ

    【第 2 章　リスクの評価法について知る】
    ［1］心房細動患者
    ［2］深部静脈血栓症・肺塞栓症患者

    【第 3 章　ガイドラインの治療方針について知る】
    ［1］心房細動治療ガイドライン
    ［2］静脈血栓塞栓症治療ガイドライン

    【第 4 章　心房細動患者での選択と使いかた】
    ［1］低〜中等度リスク患者の場合
    ［2］高リスク患者の場合
    ［3］ワルファリンを選択したい患者とは
    ［4］ダビガトランを選択したい患者とは
    ［5］リバーロキサバンを選択したい患者とは
    ［6］アピキサバンを選択したい患者とは
    ［7］エドキサバンを選択したい患者とは

    【第 5 章　静脈血栓塞栓症患者での選択と使いかた】
    ［1］深部静脈血栓症のみの患者の場合
    ［2］肺塞栓症を合併した患者の場合
    ［3］ワルファリンを選択したい患者とは
    ［4］ヘパリンを選択したい患者とは
    ［5］ｔ−ＰＡを選択したい患者とは
    ［6］エドキサバンを選択したい患者とは
    ［7］リバーロキサバンを選択したい患者とは
    ［8］アピキサバンを選択したい患者とは

    【第 6 章　私ならこの薬を選ぶ：実例の呈示】
    ＜心房細動患者編＞
    ［1］ワルファリン
    ［2］ダビガトラン
    ［3］リバーロキサバン
    ［4］アピキサバン
    ［5］エドキサバン
    ［6］ヘパリン
    ＜深部静脈血栓症・肺塞栓症患者編＞
    ［1］ワルファリン
    ［2］リバーロキサバン
    ［3］アピキサバン
    ［4］エドキサバン
    ［5］ヘパリン
    ［6］フォンダパリヌクス

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.19 掲載の参考文献
1) Bonaca, MP. et al. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 116, 2015, 1579-98.
PubMed

第1章 抗凝固薬の特徴を踏まえる

P.27 掲載の参考文献
1) Warfarin 適正使用情報. 2014年8月更新第4版. 東京, エーザイ株式会社.
 
2) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧)
 
3) Yasaka, M. et al. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. Intern Med. 40, 2001, 1183-8.
PubMed
P.33 掲載の参考文献
1) Connolly, SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 361, 2009, 1139-51.
 
2) Connolly, SJ. et al. Additional events in the RE-LY trial. N Engl J Med. 371, 2014, 1464-5.
 
3) Hijazi, Z. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 129, 2014, 961-70.
PubMed
4) Yao, X. et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 13, 2016, pii : e003725.
 
P.39 掲載の参考文献
1) Tanigawa, T. et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 28, 2013, 59-70.
PubMed
2) Patel, MR. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 365, 2011, 883-91.
PubMed
3) Hori, M. et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation? the J-ROCKET AF study?. Circ J. 76, 2012, 2104-11.
 
4) イグザレルト(R)錠適正使用ガイド. バイエル薬品
 
5) イグザレルト(R)錠特定使用成績調査の現状報告. バイエル薬品
 
P.47 掲載の参考文献
1) Granger, CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365, 2011, 981-92.
PubMed
2) Agnelli, G. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 369, 2013, 799-808.
PubMed
3) Akao, M. et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey : The Fushimi AF Registry. J Cardiol. 61, 2013, 260-6.
 
4) 川原直子ほか. 伏見心房細動患者登録研究におけるアピキサバン投与量減量規定合致症例の割合および特徴に関する研究. 新薬と臨床. 62, 2013, 930-42.
Medical*Online
5) Akao, M. et al. Study design of J-ELD AF : A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. J Cardiol. 68, 2016, 554-8.
PubMed
P.53 掲載の参考文献
1) Ruff, CT. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation : Design and rationale for the Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 160, 2010, 635-41.
PubMed
2) Giugliano, RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 369, 2013, 2093-104.
PubMed
3) Yamashita, T. et al. Edoxaban vs. warfarin in east Asian patients with atrial fibrillation-An ENGAGE AF-TIMI 48 subanalysis. Circ J. 80, 2016, 860-9.
PubMed
4) Buller HR, I. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369, 2013, 1406-15.
PubMed
5) Koretsune, Y. et al. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal imparement. Circ J. 79, 2015, 1486-95.
 
P.65 掲載の参考文献
1) Sakuragawa, N. et al. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) --a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 72, 1993, 475-500.
PubMed
2) Yusuf, S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA. 295, 2006, 1519-30.
PubMed
3) Buller, HR. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : a randomized trial. Ann Inter Med. 140, 2004, 867-73.
 
4) アリクストラ(R)皮下注1.5mg/アリクストラ(R)皮下注2.5mg 添付文章情報 (第6版)
 
5) アリクストラ(R)皮下注5mg/アリクストラ(R)皮下注7.5mg 添付文書情報 (第4版).
 
6) 久米川一郎. ほか. 下肢整形外科手術施行患者に対するアリクストラ(R)皮下注 (フォンダパリヌクスナトリウム) の特定使用成績調査. 臨床医薬. 28, 2012, 505-27.
Medical*Online
7) 安部博晴. ほか. 一般外科における腹部手術施行患者を対象としたアリクストラ(R)皮下注 (フォンダパリヌクスナトリウム) の特定使用成績調査. 臨床医薬. 30, 2014, 943-55.
Medical*Online
8) 安部博晴, ほか. 泌尿器科, 産科, 婦人科におけるVTE高リスク腹部手術施行患者を対象としたアリクストラ(R)皮下注 (フォンダパリヌクスナトリウム) の特定使用成績調査. 臨床医薬. 31, 2015, 629-43.
Medical*Online
9) Nakamura, M. et al. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J. 75, 2011, 1424-32.
PubMed
P.69 掲載の参考文献
1) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 333, 1995, 1581-7.
 
2) Yamaguchi, T. et al. Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke. 37, 2006, 1810-5.
 
3) Hacke, W. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 359, 2008, 1317-29.
PubMed
4) Anderson, CS. et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. N Engl J Med. 374, 2016, 2313-23.
PubMed
5) 日本脳卒中学会医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針. 第二版. 脳卒中. 34, 2012, 443-80.
 
6) Kirchhof, P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS : The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 37, 2016, 2893-962.
 
7) Diener, HC. et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke : Expert opinion. Int J Stroke. 12, 2017, 9-12.
PubMed

第2章 リスクの評価法について知る

P.76 掲載の参考文献
1) Gage, BF. et al. Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA. 285, 2001, 2864-70.
 
2) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧).
 
3) 日本脳卒中学会脳卒中ガイドライン委員会編. 3-1 危険因子の管理 (4) 心房細動. 脳卒中治療ガイドライン2015. 東京, 協和企画, 2015, 32-5.
 
4) Lip, GY. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. Chest. 137, 2010, 263-72.
PubMed
5) Camm, AJ. et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 31, 2010, 2369-429.
PubMed
6) Olesen, JB. et al. The value of the CHA2DS2-VASc score for refining stroke stratification in patients with atrial fibrillation with CHADS2 score 0-1 : a nationwide cohort study. Thromb Haemost. 107, 2012, 1172-9.
 
7) Inoue, H. et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol. 113, 2014, 957-62.
PubMed
8) Tomita, F. et al. Prevalence and clinical characteristics of patients with atrial fibrillation : analysis of 20,000 cases in Japan. Jpn Circ J. 64, 2000, 653-8.
PubMed
9) Steinberg, BA. et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation : results from the ROCKET-AF trial. Eur Heart J. 36, 2015, 288-96.
PubMed
10) Kleemann, T. et al. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr. 10, 2009, 383-8.
PubMed
11) Nakamura, M. et al. Plasma B-type natriuretic peptide as a predictor of cardiovascular events in subjects with atrial fibrillation : a community-based study. PLoS One. 8, 2013, e81243.
PubMed
12) Nozawa, T. et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 109, 2006, 59-65.
PubMed
13) Piccini, JP. et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation : validation of the R (2) CHADS (2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 127, 2013, 224-32.
 
14) Chao, TF. et al. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation--could it refine clinical risk stratification in AF?. Int J Cardiol. 170, 2014, 344-9.
PubMed
P.80 掲載の参考文献
1) Konstantinides, SV. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35, 2014, 3033-69.
PubMed
2) Prandoni, P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 92, 2007, 199-205.
PubMed
3) Douketis, JD. et al. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med. 110, 2001, 515-9.
PubMed
4) Kearon, C. et al. Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest. 149, 2016, 315-52.
 
5) Pacouret, G. et al. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximaldeep venous thrombosis. A prospective study. Arch Intern Med. 157, 1997, 305-8.
 
6) Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest. 138, 2010, 1093-100.
PubMed
7) Kearon, C. et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141 (2 Suppl), 2012, e419S-94S.
 
8) Riva, N. et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost. 112, 2014, 511-21.
PubMed

第3章 ガイドラインの治療方針について知る

P.87 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧).
 
2) January, CT. et al. 2014 AHA/ACC/HRS guideline for the managementof patients with atrial fibrillation : a report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines and theHeart Rhythm Society. J Am Coll Cardiol. 64, 2014, e1-76.
 
3) Kirchhof, P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS : The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of theESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016, pii : ehw210.
 
P.94 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2017年1月閲覧).
 
2) Konstantinides, SV. et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35, 2014, 3033-69.
 
3) Kearon, C. et al. Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest 149, 2016, 315-52.
 

第4章 心房細動患者での選択と使いかた

P.102 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) 心房細動治療 (薬物) 治療ガイドライン (2013年改訂版). 2014. http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧)
 
2) Gage, BF. et al. Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA. 285, 2001, 2864-70.
 
3) Suzuki, S. et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 79, 2015, 432-8.
 
4) Atarashi, H. et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation-A report from the J-RHYTHM Registry. Circ J. 75, 2011, 1328-33.
 
5) Akao, M. et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey : the Fushimi AF Registry. J Cardiol. 61, 2013, 260-6.
 
6) Toyoda, K. et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan : the SAMURAI-NVAF study. Int J Stroke. 10, 2015, 836-42.
PubMed
7) Connolly, SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361, 2009, 1139-51.
PubMed
8) Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365, 2011, 981-992.
PubMed
9) Oldgren, J. et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 Score : A Subgroup Analysis of the RE-LY Trial. Ann Intern Med. 155, 2011, 660-7.
 
10) Patel, MR. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365, 2011, 883-91.
PubMed
11) Hori, M. et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation -the J-ROCKET AF study-. Circ J. 76, 2012, 2104-11.
 
12) Ogawa, S. et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation : insights from the rivaroxaban postmarketing surveillance registry. J Stroke Cerebrovasc Dis. 23, 2014, 2520-6.
PubMed
13) Kodani, E. et al. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation : A Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 5, 2016, e004075. doi:10.1161/JAHA.116.004075.
 
14) Singer, DE. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 151, 2009, 297-305.
PubMed
15) Lip, GY. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation. Chest. 137, 2010, 263-72.
PubMed
16) Camm, AJ. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 33, 2012, 2719-47.
PubMed
17) Lip, GY. et al. Identifying patients at high risk for stroke despite anticoagulation : a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 41, 2010, 2731-8.
 
18) Hamatani, Y. et al. Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation : The Fushimi AF Registry. PLoS One. 10, 2015, e0142394.
PubMed
19) Banerjee, A. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population : a modelling analysis based on a nationwide cohort study. Thromb Haemost. 107, 2012, 584-9.
 
P.107 掲載の参考文献
1) Potpara, TS. et al. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Prog Cardiovasc Dis. 58, 2015, 177-94.
PubMed
2) Kodani, E. et al. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation : A Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc, 12, 2016. 5.
 
3) Kumar, S. et al. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation : A Meta-Analysis of Randomized Controlled Trials. Cardiol Rev. 24, 2016, 24, 218-23.
PubMed
4) Flack, KF. et al. Major Gastrointestinal Bleeding is Often Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clin Gastroenterol Hepatol. pii : S1542-3565(16)30928-4.
PubMed
5) Ho, P. et al. Direct oral anticoagulants in frail older adults : a geriatric perspective. Seminars in thrombosis and hemostasis. 41, 2015, 389-94.
PubMed
6) Eikelboom, JW. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 123, 2011, 2363-72.
PubMed
7) Halperin, JL. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 130, 2014, 138-46.
PubMed
8) Halvorsen, S. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial. European heart journal. 35, 2014, 1864-72.
PubMed
9) Kato, ET. et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 5, 2016. pii : e003432.
 
10) Hijazi, Z. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 129, 2014, 961-70.
PubMed
11) Goodman, SG. et al. Factors associated with major bleeding events : insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 63, 2014, 891-900.
PubMed
12) Hohnloser, SH. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial. Eur Heart J. 33, 2012, 2821-30.
PubMed
13) Bohula, EA. et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 134, 2016, 24-36.
PubMed
14) Rockwood, K. et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 173, 2005, 489-95.
PubMed
P.111 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧).
 
2) Eikelboom, JW. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 369, 2013, 1206-14.
PubMed
3) January, CT. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline and the Heart Rhythm Society. J Am Coll Cardiol. 64, 2014, e1-e76.
 
4) Ho, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin : impact of quality of anticoagulation control. Stroke. 46, 2015, 23-30.
PubMed
P.115 掲載の参考文献
1) Connolly, SJ. et al. RE-LY steering committee and investigators, dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med. 361, 2009, 1139-51.
Medical*Online
2) Connoly, SJ. et al. Additional events in the RE-LY trial. N Engl J Med. 371, 2014, 1464-5.
 
3) Patel, MR. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365, 2011, 883-91.
PubMed
4) Granger, CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365, 2011, 981-92.
PubMed
5) Giugliano, RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 369, 2013, 2093-104.
PubMed
6) Komori, M. et al. Intracranial hemorrhage during dabigatran treatment. Circ J. 78, 2014, 1335-41.
PubMed
7) Pollack, CV J. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 373, 2015, 511-20.
PubMed
8) Hori, M. et al. Dabigatran versus warfarin : effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation. Stroke. 44, 2013, 1891-6.
PubMed
P.120 掲載の参考文献
1) Pearson, S. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365, 2011, 2334-5.
PubMed
2) Hori, M. et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation : the J-ROCKET AF study. Circ J. 76, 2012, 2104-11.
 
3) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2016年12月閲覧).
 
4) Cappato, R. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 35, 2014, 3346-55.
PubMed
5) Enomoto, T. et al. The Efficacy and Safety of Oral Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Scheduledfor Electrical Cardioversion. Intern Med. 55, 2016, 1953-8.
 
6) Lip, GY. et al. Left atrial thrombus resolution in atrial fibrillation or flutter : Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 178, 2016, 126-34.
 
7) Cappato, R. et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvularatrial fibrillation. Eur Heart J. 36, 2015, 1805-11.
 
P.123 掲載の参考文献
1) Connolly, SJ. et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 364, 2011, 806-17.
PubMed
2) Granger, CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365, 2011, 981-92.
PubMed
P.127 掲載の参考文献
1) Giugliano, RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 369, 2013, 2093-104.
PubMed
2) Buller, HR. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369, 2013, 1406-15.
PubMed
3) Kato, ET. et al. Efficacy and safety of Edoxaban in Elderly Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 5, 2016, e003432.
 
4) Ruff, CT. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomized trials. Lancet. 383, 2013, 955-62.
PubMed
5) Yamashita, T. et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation -An ENGAGE AF-TIMI 48 subanalysis-. Circ J. 80, 2016, 860-9.
PubMed
6) Rost, NS. et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events : findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 47, 2016, 2075-82.
PubMed

第5章 静脈血栓塞栓症患者での選択と使いかた

P.134 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2016年12月閲覧).
 
2) Hokusai-VTE Investigators. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369, 2013, 1406-15.
PubMed
3) Yamada, N. et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thromb J. 12, 2015, 2.
 
4) Nakamura, M. et al. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ J. 79, 2015, 1230-6.
PubMed
5) Cheung, YW, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost. 116, 2016, 733-8.
PubMed
6) Kearon, C. et al. Antithrombotic therapy for VTE disease : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141, 2012, e419S-494S.
PubMed
7) Suzuki, K. et al. Impact of edoxaban approval for venous thromboembolism on length of hospitalization. Jpn J Thromb Hemost. (in press)
 
P.138 掲載の参考文献
1) Partsch, H. Ambulation and compression after deep vein thrombosis : dispelling myths. Semin Vasc Surg. 18, 2005, 148-52.
PubMed
2) Nakamura, M. et al. Current venous thromboembolism management and outcomes in Japan. Circ J 78, 2014, 708-17.
PubMed
3) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2016年12月閲覧).
 
4) Konstantinides, SV. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35, 2014, 3033-69, 3069a-3069k.
 
P.142 掲載の参考文献
1) Alexander, JH. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 365, 2011, 699-708.
PubMed
2) Mega, JL. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 366, 2012, 9-19.
PubMed
3) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). Circ J. 75, 2011, 1258-81. http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2016年12月閲覧).
 
P.147 掲載の参考文献
1) Goldhaber, SZ. et al. Acute pulmonary embolism : clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353, 1999, 1386-9.
PubMed
2) Konstantinides, SV. et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35, 2014, 3033-80.
PubMed
3) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2016年12月閲覧)
 
4) Torbicki, A. et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 29, 2008, 2276-315.
PubMed
5) Kearon, C. et al. Antithrombotic therapy for VTE disease Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141, 2012, e419S-e494S.
PubMed
6) Linkins, LA. et al. Treatment and prevention of heparin-induced thrombocytopenia : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141, 2012, e495S-e530S.
PubMed
7) Lyman, GH. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 11, 2015, e442-e444.
 
8) Kearon, C. et al. Antithrombotic therapy for VTE disease CHEST Guideline and Expert Panel Report. Chest. 149, 2016, 315-52.
 
9) Posch, F. et al. Treatment of venous thromboembolism in patients with cancer : a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Research. 136, 2015, 582-9.
 
10) Bates, AM. et al. VTE, thrombophillia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis. 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141, 2012, e691S-e736S.
 
11) 日本産科婦人科学会, 日本産婦人科学会. 産婦人科診療ガイドライン-産科編2014. http://www.jsog.or.jp/activity/pdf/gl_sanka_2014.pdf (2016年11月閲覧).
 
12) Black, SA. et al. Anticoagulation strategies for venous thromboembolism : moving towards a personalized approach. Thromb Heamost. 114, 2015, 660-9.
PubMed
13) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. Medical Front International Limited. 東京, 2004.
 
P.150 掲載の参考文献
1) 日本脳卒中学会脳卒中医療向上・社会保険委員会 rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針. 第二版. 脳卒中. 34, 2012, 443-80.
 
2) 日本脳卒中学会脳卒中ガイドライン委員会. "脳静脈・静脈洞閉塞症". 脳卒中治療ガイドライン2015. 東京, 協和企画, 2015, 252-4.
 
P.155 掲載の参考文献
1) Buller, HR. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369, 2013, 1406-15.
PubMed
2) Konstantinides, S. et al. 2014 ESC guideline on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35, 2014, 3033-73.
PubMed
P.160 掲載の参考文献
1) Bauersachs, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 363, 2010, 2499-510.
PubMed
2) Buller, HR. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 366, 2012, 1287-97.
PubMed
3) Prins, MH. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE) : a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 1, 2014, e37-46.
 
4) Yamada, N. et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thromb J. 13, 2015, 2.
 
5) Ageno, W. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA) : an international, prospective, non-interventional study. Lancet Haematol. 3, 2016, e12-21.
PubMed
P.164 掲載の参考文献
1) Agnelli, G. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 369, 2013, 799-808.
PubMed
2) Nakamura, M. et al. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ J. 79, 2015, 1230-6.
PubMed
3) Limone. BL. et al. Timing of recurrent venous thromboembolism early after the index event : a meta-analysis of randomized controlled trials. Thromb Res. 132, 2013, 420-6.
PubMed
4) Granger, CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 365, 2011, 981-92.
PubMed
5) Halvorsen, S. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial. Eur Heart J. 35, 2014, 1864-72.
PubMed

第6章 私ならこの薬を選ぶ : 実例の呈示

P.170 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会. 脳卒中治療ガイドライン2015. 東京, 協和企画, 2015.
 
2) Barnes, GD. et al. Direct oral anticoagulants : unique properties and practical approaches to management. Heart. 102, 2016, 1620-6.
PubMed
P.181 掲載の参考文献
1) Shields, AM. et al. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med. 278, 2015, 1-18.
PubMed
P.186 掲載の参考文献
1) Nakamura, K. et al. Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation. Circ J. 80, 2016, 870-7.
PubMed
2) Okishige, K. et al. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. J Cardiol. 69, 2017, 11-5.
PubMed
P.201 掲載の参考文献
1) Koitabashi, N. et al. Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment. Thromb J. 13, 2015, 13.
PubMed
2) Yamada, N. et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thromb J. 13, 2015, 2.
 
3) 小板橋紀通. 静脈血栓塞栓症に対するリバーロキサバンの初期血栓退縮効果の検討. Prog Med. 36, 2016, 807-16.
Medical*Online
P.210 掲載の参考文献
1) Nakamura, M. et al. Current Venous Thromboembolism Management and Outcomes in Japan. Circ J. 78, 2014, 708-17.
PubMed
2) Khorana, AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 125, 2010, 490-3.
PubMed
3) Zamorano, JL. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 37, 2016, 2768-801.
 
4) 向井幹夫. 併存症のある心房細動症例-この患者の抗凝固療法をどうするか? 担癌患者. 薬局. 67, 2016, 2391-6.
 
5) リクシアナ(R)錠. 添付文書. 2014年9月改訂 (第3版). 第一三共.
 
P.214 掲載の参考文献
1) Homma, S. et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 366, 2012, 1859-69.
PubMed

書評

最近チェックした商品履歴

Loading...